Clinical Trial

A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial is a single-center, open-label, non-randomized first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of SNA028 (which is a two-step radioactivity pretargeting agents conducted by GPA33-CC and 177Lu-SmartD2) in patients with GPA33-positive colorectal cancer who have experienced disease progression/recurrence following prior standard therapy.
Trial Details
NCT Number NCT07590856
Lead Sponsor SmartNuclide Biopharma
Collaborators: Tianjin Medical University Cancer Institute and Hospital
Conditions Colorectal Cancer
Enrollment 20 participants
Start Date 2026-05-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15